ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,261 to 4,280 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): Number of Participants Who Used Image Guidance Approach383 of 753

399 of 747

-2.6 points

-7.6 to 2.5

1,500NCT02100228

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

FFR Guided PCI vs CABG: Number of Participants Experiencing BARC Type 3-5 Bleeding12 of 757

28 of 743

-2.2 points

-3.9 to -0.5

1,500NCT02100722

A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

FFR Guided PCI vs CABG: Death, MI, or Stroke at 5 Years119 of 757

101 of 743

2.1 points

-1.5 to 5.7

1,500NCT02100722

A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

FFR Guided PCI vs CABG: Number of Participants Experiencing Death, MI, or Stroke55 of 757

39 of 743

2.0 points

-0.5 to 4.5

1,500NCT02100722

A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

FFR Guided PCI vs CABG: Number of Participants Requiring Rehospitalization Within 30 Days42 of 757

76 of 743

-4.7 points

-7.5 to -2.0

1,500NCT02100722

A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

FFR Guided PCI vs CABG: MACCE188 of 757

131 of 743

7.2 points

3.1 to 11.3

1,500NCT02100722

A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

FFR Guided PCI vs CABG: Key Secondary Outcome: Composite of Death From Any Cause, Myocardial Infarction, or Stroke91 of 757

68 of 743

2.9 points

-0.3 to 6.0

1,500NCT02100722

A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

FFR Guided PCI vs CABG: Number of Participants Experiencing Atrial Fibrillation or Clinically Significant Arrhythmia18 of 757

105 of 743

-11.8 points

-14.6 to -9.1

1,500NCT02100722

A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

FFR Guided PCI vs CABG: MACCE80 of 757

51 of 743

3.7 points

0.8 to 6.6

1,500NCT02100722

A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

FFR Guided PCI vs CABG: deaths from any cause31 of 757

29 of 743

0.2 points

-1.8 to 2.2

1,500NCT02100722

A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

FFR Guided PCI vs CABG: serious adverse events119 of 757

101 of 743

2.1 points

-1.5 to 5.7

1,500NCT02100722

A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

GSK3390107A Group vs Placebo+GSK3390107A Group: Number of Subjects With Unsolicited Adverse Events (AEs)123 of 749

119 of 751

0.6 points

-3.2 to 4.3

1,500NCT02485301

A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults

Everolimus vs Placebo: deaths from any cause139 of 755

151 of 744

-1.9 points

-5.9 to 2.1

1,499NCT01120249

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

SCH 697243 vs Placebo: serious adverse events14 of 753

9 of 745

0.7 points

-0.7 to 2.0

1,498NCT01385371

A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)

Home Nurse Visit vs Control: Number of Participants With Occurrence(s) of an Unplanned Readmission Within 30 Days Post-discharge58 of 749

41 of 749

2.3 points

-0.3 to 4.8

1,498NCT02081846

Hospital to Home Outcomes

Home Nurse Visit vs Control: Number of Participants With Any Occurrence of Unplanned Re-hospitalization and/or Any Emergency/Urgent Care Visits Within 30 Days of Hospital Discharge133 of 749

105 of 749

3.7 points

0.0 to 7.4

1,498NCT02081846

Hospital to Home Outcomes

Home Nurse Visit vs Control: Number of Participants With Occurrence(s) of 14-day Unplanned Healthcare Utilization132 of 749

110 of 749

2.9 points

-0.8 to 6.7

1,498NCT02081846

Hospital to Home Outcomes

Home Nurse Visit vs Control: Number of Participants With Occurrence(s) of an Emergency Department Visit Within 30 Days Post-discharge75 of 749

54 of 749

2.8 points

-0.0 to 5.7

1,498NCT02081846

Hospital to Home Outcomes

Acute Phase: ZS vs Extended Dosing Phase: ZS: deaths from any cause0 of 751

8 of 746

-1.1 points

-2.1 to -0.3

1,497NCT02163499

Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months

Acute Phase: ZS vs Extended Dosing Phase: ZS: serious adverse events1 of 751

161 of 746

-21.4 points

-24.5 to -18.6

1,497NCT02163499

Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=214"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=214

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02100228-f1d663f1",
        "title": "Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): Number of Participants Who Used Image Guidance Approach",
        "summary": "383 of 753 against 399 of 747; risk difference -2.6 points, 95% interval -7.6 to 2.5; NCT02100228, Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)",
        "record": "/library/comparisons/NCT02100228-f1d663f1",
        "nct_id": "NCT02100228",
        "kind": "outcome",
        "participants": 1500,
        "risk_difference": {
          "value": -0.025504408070529117,
          "lower": -0.07582681851416401,
          "upper": 0.025003309981620918
        },
        "group_1": "383 of 753",
        "group_2": "399 of 747",
        "difference": "-2.6 points",
        "interval": "-7.6 to 2.5",
        "trial_title": "Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)"
      },
      {
        "id": "NCT02100722-11c2e907",
        "title": "FFR Guided PCI vs CABG: Number of Participants Experiencing BARC Type 3-5 Bleeding",
        "summary": "12 of 757 against 28 of 743; risk difference -2.2 points, 95% interval -3.9 to -0.5; NCT02100722, A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease",
        "record": "/library/comparisons/NCT02100722-11c2e907",
        "nct_id": "NCT02100722",
        "kind": "outcome",
        "participants": 1500,
        "risk_difference": {
          "value": -0.02183301300913324,
          "lower": -0.03942526078675258,
          "upper": -0.005473522214226142
        },
        "group_1": "12 of 757",
        "group_2": "28 of 743",
        "difference": "-2.2 points",
        "interval": "-3.9 to -0.5",
        "trial_title": "A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=215",
  "request_id": "toeljlPGK5s4dlzc"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?